Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label sunitinib continuation protocol after prior sunitinib study
2006-006538-16Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sunitinib in gastrointestinal stromal tumor (GIST), breast cancer, renal cell carcinoma (RCC) and 6 more, sponsored by Pfizer. Primary endpoints: Long-term safety, Tolerability and 1 more. Started Feb 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
gastrointestinal stromal tumor (GIST)breast cancerrenal cell carcinoma (RCC)islet cell tumorhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2006-006538-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006538-16.